Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial.

@article{Bobo2014EffectOA,
  title={Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial.},
  author={William V. Bobo and Noreen A. Reilly-Harrington and Terence A. Ketter and Benjamin D Brody and Gustavo Kinrys and David Eric Kemp and Richard Charles Shelton and Susan L. McElroy and Louisa G Sylvia and James H. Kocsis and Melvin G. McInnis and Edward S. Friedman and Vivek Singh and Mauricio Tohen and Charles L. Bowden and Thilo Deckersbach and Joseph R. Calabrese and Michael E. Thase and Andrew A. Nierenberg and Dustin J Rabideau and David Alan Schoenfeld and Stephen V. Faraone and Masoud Kamali},
  journal={Journal of affective disorders},
  year={2014},
  volume={161},
  pages={
          30-5
        }
}
BACKGROUND Little is known about the longer-term effects of adjunctive benzodiazepines on symptom response during treatment in patients with bipolar disorders. METHODS The study sample consisted of 482 patients with bipolar I or II disorder enrolled in a 6-month, randomized, multi-site comparison of lithium- and quetiapine-based treatment. Changes in clinical measures (BISS total and subscales, CGI-BP, and CGI-Efficacy Index) were compared between participants who did and did not receive… Expand
Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium.
TLDR
The Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE) study was the first comparative effectiveness assessment of lithium versus quetiapine (in combination with adjunctive personalized treatment), and found no overall significant differences in efficacy and safety/tolerability outcomes. Expand
The use of antidepressant medications for Bipolar I and II disorders
TLDR
Comparing socio-demographic and clinical features of BD patients treated vs. not treated with ADs may help clinicians to better understand the clinical correlates of BD subtypes and improve their differential management. Expand
The use of benzodiazepines in bipolar disorders
TLDR
Although benzodiazepines have many benefits for patients with bipolar disorders, their use must be very cautious, because of the associated risk of misuse and other possible consequences, especially in some particular clinical situations. Expand
Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale.
TLDR
Given its ability to identify patients with co-occurring anxiety, the BISS anxiety subscale shows clinical utility as a screening measure though its application as a clinical assessment measure may not be advisable. Expand
A retrospective record review and assessment of cost of quetiapine use in a community psychiatric setting in the Sedibeng district of Gauteng
TLDR
Quetiapine use was associated with a highly significant improvement in functioning; however, it came at a 52% increase in medicine cost, and overall costs may be reduced by more rational prescribing habits. Expand
Risk of psychiatric disorders in patients with chronic insomnia and sedative-hypnotic prescription: a nationwide population-based follow-up study.
TLDR
The results regarding patients with insomnia and sedative-hypnotic prescriptions associated with the risk of psychiatric disorders can serve as a reference for care providers when managing sleep disturbances. Expand
Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors.
TLDR
BD patients with CP were less likely to adhere to therapy, and those with worse adherence to CP were more likely to clinically respond, and Clinicians should assess medication adherence prior to adding another agent to medication regimens. Expand
Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice
TLDR
A group of young Italian psychiatrists attempted to highlight possible flaws in current teaching pathways, identify the main clinical pros and cons regarding current use of BDZs in clinical practice, and provide an updated overview of their use across specific clinical areas and patient populations. Expand
Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis
TLDR
The current meta-analysis confirms that GAD is highly prevalent in BD and the rate is higher in comparison to those in the general population and it is unknown how best to treat such conditions. Expand
Chapter 3 - Lithium
TLDR
This review discusses recent literature on short- and long-term adverse effects of lithium and provides insight on how to monitor and manage these adverse effects. Expand
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder
Abstract The value of a long-term treatment with clonazepam in the prophylaxis of affective disorder is discussed controversially in the scientific literature. Altogether there are only a few reportsExpand
The effects of benzodiazepines on cognition.
TLDR
Findings suggest that patients should be advised of potential cognitive effects when treated long term with benzodiazepines, although they should also be informed that the impact of such effects may be insignificant in the daily functioning of most patients. Expand
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
  • G. Chouinard
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2004
TLDR
Although as a class benzodiazepines act rapidly and are well tolerated, their use presents clinical issues such as dependence, rebound anxiety, memory impairment, and discontinuation syndrome. Expand
Do benzodiazepines extend the duration of follow‐up treatment in patients with bipolar disorder?
TLDR
Whether there is any association between benzodiazepine (BZD) use and the duration of follow‐up treatment in patients with bipolar disorder is examined. Expand
Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders.
TLDR
Antidepressants were the first-choice agent twice as often as mood stabilizers to treat bipolar disorder, and Lithium was sustained longer than monotherapy with other Mood stabilizers. Expand
Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders.
TLDR
Prescription benzodiazepine use was common among patients with co-occurring severe mental illness and a substance use disorder and was not associated with any of the measured outcomes other than increasing the likelihood of benzodiazine abuse. Expand
Mania: Diagnosis and Treatment Recommendations
TLDR
Recommendations for the diagnosis and treatment of mania, which characterizes bipolar I disorder (BD I), are provided, by synthesizing the findings from recent treatment guidelines, and reviewing relevant literature. Expand
Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP
TLDR
The modified CGI-BP is anticipated to be more useful than the original CGI in studies of bipolar disorder and interrater reliability of the scale was demonstrated in preliminary analyses. Expand
Cognitive Effects of Long-Term Benzodiazepine Use
TLDR
The observation that long-term benzodiazepine use leads to a generalised effect on cognition has numerous implications for the informed and responsible prescription of these drugs. Expand
Benzodiazepine prescription practices and substance abuse in persons with severe mental illness.
TLDR
Contrary to published guidelines, rates of benzodiazepine use are higher among Medicaid beneficiaries with severe mental illness and co-occurring SUD than among persons with severemental illness alone. Expand
...
1
2
...